Knowledge graph · Cancer
Bladder Carcinoma
subtype
- Identifier
- CI-CAN-00007316
- Entity page
- /cancer/bladder-carcinoma ↗
- Edges
- 865
- Neighbours
- 24 genes12 variants27 drugs10 trials
- Drawn
- 60 of 73 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Bladder Carcinoma approved for …APPROVED_FOR8 of 7 | ||||||||
| ← approved for | Thiotepasmall_molecule | supports | FDA ORIG | Bladder Carcinoma | 1 | Regulatory | openfda | graph → |
| ← approved for | Nadofaragene Firadenovecgene therapy EMA (EU) · approved · 2026-05-28 · Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle inv… | |||||||